Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

BUSM professor receives 2011 ACN Communication Media Award

BUSM professor receives 2011 ACN Communication Media Award

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

New-onset AF, severe sepsis may increase risk of stroke and mortality in hospital settings

New-onset AF, severe sepsis may increase risk of stroke and mortality in hospital settings

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

HDM and SCT increase overall survival for patients with AL amyloidosis

HDM and SCT increase overall survival for patients with AL amyloidosis

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Nephros submits new 510(k) application with FDA for clearance of hemodiafiltration system

Nephros submits new 510(k) application with FDA for clearance of hemodiafiltration system

BELLUS Health second quarter revenues increase to $719,000

BELLUS Health second quarter revenues increase to $719,000

Alnylam second quarter revenue decreases to $20.6 million

Alnylam second quarter revenue decreases to $20.6 million

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Experts present new research at 2011 Alzheimer's Association ICAD

Experts present new research at 2011 Alzheimer's Association ICAD

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Solution for treating obesity-related diseases may reside in fat tissue

Solution for treating obesity-related diseases may reside in fat tissue

Adipose tissue might serve as target for treating obesity-related disorders

Adipose tissue might serve as target for treating obesity-related disorders

Amyloid peptide Aβ43 may serve as biomarker for diagnosis of Alzheimer's

Amyloid peptide Aβ43 may serve as biomarker for diagnosis of Alzheimer's

Potential new approach for treating myelofibrosis

Potential new approach for treating myelofibrosis